Blog 1: The birth of PDRN: from hospital wards to beauty clinics

Author: Dr. Lalit S. Rane

How a medical breakthrough in Italian hospitals became the cornerstone of modern regenerative aesthetics and why the story doesn’t end with salmon

A Discovery Born from Desperation

Picture a hospital ward in Northern Italy in the early 1990s, the kind you might see in archival medical photography, with long corridors, high ceilings, and natural light streaming through tall windows. Doctors make their rounds, pausing at bedsides where stubborn wounds and ischemic ulcers refuse to heal. These are the difficult cases, patients whose tissue damage resists even the best dressings and antibiotics. Week after week, the wounds remain open, putting patients at risk of infection, amputation, and worse.

The statistics were sobering. Research published in Diabetes Care would later show that approximately 15% of patients with diabetic foot ulcers would face amputation within five years. For elderly patients with peripheral artery disease, chronic leg ulcers meant not just pain but loss of mobility and independence.

In this challenging environment at institutions like the University of Milan and medical centers in Turin, pioneering teams began experimenting with an unconventional approach: biological extracts rich in DNA. Perhaps something in the fundamental building blocks of life could unlock the body’s healing capacity.

What they observed was remarkable. Tissue that had been stagnant for months started to heal faster. Blood flow to damaged areas visibly improved. Most striking, the quality of newly formed skin looked better than conventional treatments achieved, more organized, more resilient, more like healthy tissue. These findings would later be documented in Wound Repair and Regeneration journal, validating what clinicians were seeing firsthand.

These weren’t placebo effects. Wound surface area decreased measurably, granulation tissue appeared more robust, and time to closure shortened significantly. Patients facing amputation were keeping their limbs.

The Hunt for the Active Ingredient

Imagine a modern laboratory scene, centrifuges spinning, glass beakers containing clear solutions, sophisticated chromatography equipment humming in the background. The early successes sparked intense curiosity. What was driving this effect? The crude extracts contained proteins, lipids, nucleic acids, and numerous other components. Researchers systematically isolated and tested each fraction.

Through years of methodical work, a pattern emerged: the therapeutic power resided in the DNA molecules themselves, specifically, fragments of DNA in particular size ranges.

The Goldilocks Zone

Further research revealed something crucial: not just any DNA worked optimally. Whole DNA molecules were too large. Individual nucleotides were too small. The sweet spot was DNA fragments of approximately 50 to 1,500 base pairs, large enough to trigger cellular responses, small enough for practical production. This discovery, published in Frontiers in Pharmacology by Squadrito and colleagues, would become foundational to all PDRN development.

Think of it as communication: sending cells an entire encyclopedia (whole DNA) is overwhelming. Sending single letters (nucleotides) lacks information. But sending coherent paragraphs (DNA fragments) gives actionable information cells can use.

This insight meant the active principle was a defined class of molecules that could be purified, standardized, and produced consistently: polydeoxyribonucleotide, or PDRN.

From Placenta to Fish: The Source Evolution

Visualize a split-screen transition, on one side, medical illustrations of human placental tissue with its complex vascular networks; on the other, crystal-clear water where salmon navigate upstream, their silvery bodies catching sunlight. But knowing what worked and producing it reliably were different challenges. Researchers needed a DNA source that was abundant, pure, consistent, ethical, and economical.

The Placenta Era

Initial attempts used human placental tissue. It made sense, placenta is rich in nucleic acids and routinely collected after childbirth. However, this source presented insurmountable problems.

Supply inconsistency plagued production, as availability fluctuated with birth rates and hospital protocols. The ethical complexity required rigorous consent procedures, and some populations had cultural objections to human tissue use. Each placenta came from different mothers with different genetics and health status, creating significant variability in the final product. Human tissue also carries inherent pathogen transmission risks, requiring extensive testing as outlined in European Medicines Agency guidelines for human cell-based medicinal products. The regulatory hurdles for human-derived products meant stricter approval pathways that added years and costs to development.

The Fish Revolution

The breakthrough came when researchers turned to fish milt, the sperm-containing fluid from cold-water fish like salmon and trout. This pivot was brilliant: sperm cells are nature’s DNA delivery vehicles, and fish produce them abundantly.

Fish milt offered transformative advantages. Studies published in the Iranian Journal of Fisheries Sciences demonstrated that fish milt contains up to 10% DNA by weight, extraordinarily high compared to typical tissues at 0.1-1%. Small amounts of raw material yielded large quantities of purified DNA.

A single large salmon produces 200-400 grams of milt. Commercial fisheries handle thousands of fish daily, generating kilograms of milt, mostly discarded as waste. Using milt for PDRN created value from waste, aligning with circular economy principles and adding fishing industry revenue.

Farmed fish raised under controlled conditions produced consistent DNA quality. Even wild fish from specific regions showed good consistency, as documented in vascular surgery research by Bitto and colleagues. Fish pathogens generally can’t infect humans, and cold-water fish live in pristine environments with low pathogen loads, creating a favorable safety profile.

Most importantly, DNA is DNA. Watson and Crick’s 1953 discovery of the DNA double helix revealed that the structure and four nucleotide bases are virtually identical across vertebrates. Human cells read and respond to fish DNA fragments just as they would human DNA, it’s a universal molecular language.

Creating Medical-Grade PDRN

Picture a pharmaceutical production facility, stainless steel tanks, automated filtration systems, and quality control laboratories where technicians in white coats examine samples under microscopes and analyze chromatography readouts. Through the late 1990s and early 2000s, pharmaceutical companies refined sophisticated processes to transform raw fish milt into standardized medical products.

Fresh milt collected from fish processing facilities is first homogenized into a uniform mixture. Specialized enzymes are then introduced to break down cell membranes and release the DNA while carefully preserving its structural integrity. This initial extraction phase is critical, too aggressive, and the DNA becomes damaged; too gentle, and yields are too low.

Once the DNA is liberated from the cells, it undergoes multiple purification steps designed to remove everything that isn’t DNA. Proteins, lipids, RNA, cellular debris, and other contaminants are systematically eliminated through precipitation, filtration, and chromatography techniques. What remains after this intensive purification is highly pure DNA, often exceeding 95% purity.

The purified DNA then enters the fragmentation stage, where controlled enzymatic digestion carefully cuts the long DNA molecules into the optimal therapeutic size range of 50 to 1,500 base pairs. This step requires precise control and monitoring, the enzymes must work just long enough to achieve the target fragment size without over-digesting into pieces that are too small to be effective.

Before the PDRN can be used medically, it undergoes rigorous quality control testing. Each batch is analyzed for molecular weight distribution to ensure fragments fall within the therapeutic range, tested for sterility to confirm absence of viable microorganisms, checked for endotoxins that could trigger immune reactions, and verified for purity to ensure contaminants are below acceptable limits. Only batches that meet pharmaceutical-grade specifications proceed to the final stage.

Finally, the purified, fragmented PDRN is formulated into its final form, either injectable solutions with appropriate buffers and stabilizers, or topical preparations designed for skin application. As detailed in International Wound Journal publications by Rubegni and colleagues, the result is a consistent, sterile, pharmaceutical-grade product with reproducible composition and predictable therapeutic effects.

Clinical Validation: PDRN Proves Itself

Envision a clinical setting, a medical professional carefully examining and treating a chronic leg ulcer, the kind of wound that has resisted healing for months, while taking detailed measurements and photographs to document progress. With standardized PDRN, clinical research accelerated. Studies documented benefits across multiple scenarios.

Research published in International Wound Journal by Valdatta demonstrated that diabetic ulcers and pressure sores treated with PDRN closed 30-40% faster than standard care alone. Patients experienced better tissue quality and lower amputation rates, as confirmed in Archives of Plastic Surgery studies by Kim and colleagues examining peripheral tissue oxygenation in diabetic foot ulcers.

For ischemic conditions, PDRN promoted new blood vessel formation, improving circulation in peripheral artery disease and ischemic wounds. Research in Cardiovascular & Hematological Agents in Medicinal Chemistry by Altavilla showed that patients saw enhanced tissue perfusion and symptom relief through therapeutic angiogenesis.

Surgeons incorporated PDRN into protocols for complex reconstructions, seeing reduced healing time and improved outcomes, as documented by Park in Archives of Plastic Surgery research on fat graft resorption reduction.

By the mid-2000s, PDRN had earned regulatory approval in numerous countries for therapeutic use. It established itself as a valuable «regeneration helper» in wound care and vascular medicine, long before anyone considered it for beauty.

The Aesthetic Turn: From Hospital to Beauty Clinic

Picture a modern aesthetic clinic in Seoul, minimalist design, soft lighting, sleek treatment rooms with state-of-the-art equipment, a far cry from the hospital wards where PDRN began its journey. As aesthetic medicine evolved, especially in South Korea, which emerged as a cosmetic innovation hub, forward-thinking practitioners began asking: If PDRN helps severely damaged tissue repair, what could it do for photo-damaged or aging skin?

The logic was compelling. Sun exposure creates ongoing micro-damage, essentially slow-motion wounds. Acne scars represent disorganized healing. Aging skin shows reduced fibroblast activity and impaired circulation, similar to poorly healing tissue.

Korean dermatologists pioneered «skin booster» protocols, injecting PDRN to improve overall skin quality rather than just filling wrinkles. A multicenter, randomized, double-blind, placebo-controlled trial published in Dermatologic Surgery by Kim demonstrated that patients reported thicker, more resilient skin, improved texture, and reduced fine lines. Additional research in the Journal of Cosmetic and Laser Therapy by Lee confirmed effects on wrinkles around the eyes.

The concept spreads globally. Clinics offered «DNA rejuvenation» and «salmon DNA treatments.» Marketing embraced terms like «genetic repair» and «DNA skincare», capitalizing on biotech appeal and the salmon origin story.

By the 2010s, PDRN had transformed from hospital wound treatment to sought-after beauty ingredient. The «salmon DNA» narrative dominated: pristine rivers, leaping fish, pure northern waters.

One Ocean, Many Stories: Beyond Salmon

Imagine a comparison landscape, on one side, salmon leaping up waterfalls in a rushing river surrounded by forest; on the other, cod fishing vessels in the deep blue waters of a Norwegian fjord, with dramatic coastal mountains in the background. Here’s where the story becomes more interesting. The salmon narrative, while beautiful and true, obscures an important reality: PDRN’s activity doesn’t depend on coming from salmon.

DNA structure is universal across vertebrates. When processed to the same specifications, PDRN from different fish species triggers identical biological responses. Research in Photodermatology, Photoimmunology & Photomedicine by Belletti showed that your skin cells don’t read a «species passport»—they respond to fragment size, purity, and concentration.

This opens possibilities beyond salmon. In the North Atlantic, Atlantic cod produces milt equally rich in DNA. Cod fisheries in Norway, Iceland, and northern Europe are among the world’s most sustainable and carefully managed. The infrastructure for processing fish byproducts is sophisticated.

Cod-derived PDRN speaks the same molecular language as salmon PDRN, same biological activity, different regional story. For North Atlantic brands, cod offers regional authenticity aligned with local marine industries and traditions, sustainability narratives connected to well-managed traceable fisheries, economic integration supporting existing fishing communities and infrastructure, and scientific equivalence with the same efficacy but a different sourcing story.

It’s not about replacing salmon, it’s about expanding beyond a single-species narrative to recognize that PDRN’s power lies in the universal language of DNA, not in one particular fish.

The Broader Value Chain: Beyond Beauty

Visualize a circular diagram showing the complete journey, from a whole fish, to separated components (fillets, milt, bones), to refined products (PDRN vials for cosmetics, nucleotide supplements, omega-3 capsules), illustrating how nothing goes to waste. There’s another dimension rarely mentioned in beauty marketing: PDRN isn’t the only valuable product from fish milt.

When DNA fragments are broken down further, they yield nucleotides, molecules already used in animal feeds, aquaculture diets, and nutritional supplements. Research published in the Journal of Nutritional Biochemistry by Carver and Walker, along with aquaculture studies by Li examining immune function in fish, shows these support gut health, immune function, and growth in young or stressed animals.

A well-designed biorefinery can fractionate fish milt into multiple streams: high-purity PDRN for cosmetics and regenerative medicine, nucleotide fractions for animal feed and supplements, proteins and peptides for additional applications, and lipids for omega-3 concentrates.

One cod harvest yields food fillets, high-value PDRN for skincare, and nucleotide concentrates for healthier farmed fish, minimal waste, maximum value. This circular approach transforms waste into a portfolio of products, aligning with modern bioeconomy principles.

Conclusion: A Story Still Unfolding

The PDRN journey, from Italian hospital wards treating stubborn ulcers, through salmon-based medical products, into Korean aesthetic clinics, and now expanding to include cod and other marine sources, demonstrates how scientific innovation evolves.

What began as desperate attempts to heal chronic wounds became a sophisticated tool for skin rejuvenation. What started with human placenta and evolved to salmon milt is now diversifying to include other marine sources, each with unique regional stories and sustainability profiles.

Science remains constant: DNA fragments in specific ranges activate regenerative pathways and improve tissue healing. But the story is becoming richer, more diverse, and more connected to broader conversations about marine resources, circular economy, and regional biotechnology.

For consumers, this means more choice and transparency. For practitioners, it means a growing toolkit with solid scientific foundations. For researchers and industry, it means new opportunities to build sustainable value chains from ocean to skin.

The PDRN story isn’t ending with salmon, it’s just beginning to show its full potential.

References

1. Armstrong, D.G., Boulton, A.J.M., & Bus, S.A. (2017). Diabetic foot ulcers and their recurrence. New England Journal of Medicine, 376(24), 2367-2375.
2. Galeano, M., Altavilla, D., Cucinotta, D., Russo, G.T., Calò, M., Bitto, A., Marini, H., Marini, R., Adamo, E.B., Seminara, P., Minutoli, L., & Squadrito, F. (2008). Polydeoxyribonucleotide in the treatment of diabetic foot ulcers. Wound Repair and Regeneration, 16(2), 208-217.
3. Squadrito, F., Bitto, A., Irrera, N., Pizzino, G., Pallio, G., Minutoli, L., & Altavilla, D. (2014). Pharmacological activity and clinical use of PDRN. Frontiers in Pharmacology, 5, 224.
4. Tonello, G., Daglio, M., Zaccarelli, N., Sottofattori, E., Mazzei, M., & Balbi, A. (1996). Characterization and quantitation of the active polynucleotide fraction (PDRN) from human placenta, a tissue repair stimulating agent. Journal of Pharmaceutical and Biomedical Analysis, 14(11), 1555-1560.
5. European Medicines Agency. (2013). Guideline on human cell-based medicinal products. EMA/CAT/571134/2009.
6. Sheikhzadeh, N., Nofouzi, K., Delshad, S.T., & Oushani, A.K. (2012). DNA extraction and quantification from fish tissues. Iranian Journal of Fisheries Sciences, 11(3), 677-686.
7. Bitto, A., Polito, F., Irrera, N., D’Ascola, A., Avenoso, A., Nastasi, G., Campo, G.M., Micali, A., Bagnato, G., Minutoli, L., Squadrito, F., & Altavilla, D. (2008). Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of peripheral artery occlusive disease. Journal of Vascular Surgery, 48(5), 1292-1300.
8. Watson, J.D., & Crick, F.H. (1953). Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid. Nature, 171(4356), 737-738.
9. Rubegni, P., Risulo, M., Sbano, P., Miracco, C., Fimiani, M., & Andreassi, L. (2001). The role of polydeoxyribonucleotide (PDRN) in the treatment of chronic ulcers of the lower extremities: Clinical and immunohistochemical study. Drugs Under Experimental and Clinical Research, 27(5-6), 223-230.
10. Valdatta, L., Thione, A., Mortarino, C., Buoro, M., & Tuinder, S. (2004). Evaluation of the efficacy of polydeoxyribonucleotides in the healing process of autologous skin graft donor sites: A pilot study. Current Medical Research and Opinion, 20(3), 403-408.
11. Kim, J.H., Park, J.Y., Shen, Y., Im, S., Park, M.C., & Yoon, K.C. (2015). Polydeoxyribonucleotide accelerates wound healing and enhances tissue oxygenation. Archives of Plastic Surgery, 42(3), 270-276.
12. Altavilla, D., Squadrito, F., Polito, F., Irrera, N., Calò, M., Lo Cascio, P., Galeano, M., La Cava, L., Minutoli, L., Marini, H., & Bitto, A. (2011). Polydeoxyribonucleotide (PDRN): A safe approach to induce therapeutic angiogenesis in peripheral artery occlusive disease and in diabetic foot ulcers. Cardiovascular & Hematological Agents in Medicinal Chemistry, 9(4), 313-321.
13. Park, S.R., Kim, J.W., Jun, H.S., Roh, J.Y., Lee, H.Y., & Hong, I.S. (2016). The effect of polydeoxyribonucleotide on reduction of fat graft resorption. Archives of Plastic Surgery, 43(5), 446-452.
14. Kim, T.H., Ryu, H.W., Baek, J.W., & Kang, J.S. (2019). Polydeoxyribonucleotide for treating skin photoaging: A multicenter, randomized, double-blind, placebo-controlled trial. Dermatologic Surgery, 45(5), 670-678.
15. Lee, H.J., Lee, E.G., Kang, S., Sung, J.H., Chung, H.M., & Kim, D.H. (2016). Effects of polydeoxyribonucleotide in the treatment of wrinkles around the eyes. Journal of Cosmetic and Laser Therapy, 18(8), 447-451.
16. Belletti, S., Uggeri, J., Gatti, R., Govoni, P., & Guizzardi, S. (2007). Polydeoxyribonucleotide promotes cyclobutane pyrimidine dimer repair in UVB-exposed dermal fibroblasts. Photodermatology, Photoimmunology & Photomedicine, 23(5), 242-249.
17. Carver, J.D., & Walker, W.A. (1995). The role of nucleotides in human nutrition. Journal of Nutritional Biochemistry, 6(2), 58-72.
18. Li, P., Lewis, D.H., & Gatlin, D.M. (2007). Dietary oligonucleotide from yeast RNA influences immune responses and resistance of hybrid striped bass to Streptococcus iniae infection. Aquaculture, 262(1-4), 1-9.
19. Tøndervik, A., Slizyte, R., Mozuraityte, R., Standal, I.B., Aursand, I.G., & Aursand, M. (2020). Valorisation of marine rest raw materials: Isolation of high purity DNA from fish milt for biotechnological applications. Process Biochemistry, 91, 152-159.
20. European Commission. (2018). A sustainable bioeconomy for Europe: Strengthening the connection between economy, society and the environment. Directorate-General for Research and Innovation, Brussels.